Temporal metabolomics in dried bloodspots suggests multipathway disruptions in aldh5a1−/− mice, a model of succinic semialdehyde dehydrogenase deficiency

Madalyn Brown, Coleman Turgeon, Piero Rinaldo, Jean Baptiste Roullet, K. Michael Gibson

Research output: Contribution to journalReview article

Abstract

Succinic semialdehyde dehydrogenase (SSADH) deficiency (SSADHD; OMIM 271980) is a rare disorder featuring accumulation of neuroactive 4-aminobutyric acid (GABA; γ-aminobutyric acid, derived from glutamic acid) and 4-hydroxybutyric acid (γ-hydroxybutyric acid; GHB, a short-chain fatty acid analogue of GABA). Elevated GABA is predicted to disrupt the GABA shunt linking GABA transamination to the Krebs cycle and maintaining the balance of excitatory:inhibitory neurotransmitters. Similarly, GHB (or a metabolite) is predicted to impact β-oxidation flux. We explored these possibilities employing temporal metabolomics of dried bloodspots (DBS), quantifying amino acids, acylcarnitines, and guanidino- metabolites, derived from aldh5a1+/+, aldh5a1+/− and aldh5a1−/− mice (aldehyde dehydrogenase 5a1 = SSADH) at day of life (DOL) 20 and 42 days. At DOL 20, aldh5a1−/− mice had elevated C6 dicarboxylic (adipic acid) and C14 carnitines and threonine, combined with a significantly elevated ratio of threonine/[aspartic acid + alanine], in comparison to aldh5a1+/+ mice. Conversely, at DOL 42 aldh5a1−/− mice manifested decreased short chain carnitines (C0-C6), valine and glutamine, in comparison to aldh5a1+/+ mice. Guanidino species, including creatinine, creatine and guanidinoacetic acid, evolved from normal levels (DOL 20) to significantly decreased values at DOL 42 in aldh5a1−/− as compared to aldh5a1+/+ mice. Our results provide a novel temporal snapshot of the evolving metabolic profile of aldh5a1−/− mice while highlighting new pathomechanisms in SSADHD.

Original languageEnglish (US)
Pages (from-to)397-408
Number of pages12
JournalMolecular Genetics and Metabolism
Volume128
Issue number4
DOIs
StatePublished - Dec 2019

Fingerprint

Succinate-Semialdehyde Dehydrogenase
Metabolomics
gamma-Aminobutyric Acid
Carnitine
Threonine
Metabolites
Hydroxybutyrates
Aminobutyrates
Aldehyde Dehydrogenase
Creatine
Volatile Fatty Acids
Genetic Databases
Valine
Citric Acid Cycle
Metabolome
Glutamine
Aspartic Acid
Alanine
Neurotransmitter Agents
succinic semialdehyde dehydrogenase deficiency

Keywords

  • Acylcarnitines
  • aldh5a1 mice
  • Amino acids
  • Dried bloodspots
  • GABA shunt
  • Guanidino-metabolites
  • Succinic semialdehyde dehydrogenase (SSADH) deficiency (SSADHD)
  • β-oxidation

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Biology
  • Genetics
  • Endocrinology

Cite this

Temporal metabolomics in dried bloodspots suggests multipathway disruptions in aldh5a1−/− mice, a model of succinic semialdehyde dehydrogenase deficiency. / Brown, Madalyn; Turgeon, Coleman; Rinaldo, Piero; Roullet, Jean Baptiste; Gibson, K. Michael.

In: Molecular Genetics and Metabolism, Vol. 128, No. 4, 12.2019, p. 397-408.

Research output: Contribution to journalReview article

Brown, Madalyn ; Turgeon, Coleman ; Rinaldo, Piero ; Roullet, Jean Baptiste ; Gibson, K. Michael. / Temporal metabolomics in dried bloodspots suggests multipathway disruptions in aldh5a1−/− mice, a model of succinic semialdehyde dehydrogenase deficiency. In: Molecular Genetics and Metabolism. 2019 ; Vol. 128, No. 4. pp. 397-408.
@article{ec0a3ec743c14ef281190b790eabef53,
title = "Temporal metabolomics in dried bloodspots suggests multipathway disruptions in aldh5a1−/− mice, a model of succinic semialdehyde dehydrogenase deficiency",
abstract = "Succinic semialdehyde dehydrogenase (SSADH) deficiency (SSADHD; OMIM 271980) is a rare disorder featuring accumulation of neuroactive 4-aminobutyric acid (GABA; γ-aminobutyric acid, derived from glutamic acid) and 4-hydroxybutyric acid (γ-hydroxybutyric acid; GHB, a short-chain fatty acid analogue of GABA). Elevated GABA is predicted to disrupt the GABA shunt linking GABA transamination to the Krebs cycle and maintaining the balance of excitatory:inhibitory neurotransmitters. Similarly, GHB (or a metabolite) is predicted to impact β-oxidation flux. We explored these possibilities employing temporal metabolomics of dried bloodspots (DBS), quantifying amino acids, acylcarnitines, and guanidino- metabolites, derived from aldh5a1+/+, aldh5a1+/− and aldh5a1−/− mice (aldehyde dehydrogenase 5a1 = SSADH) at day of life (DOL) 20 and 42 days. At DOL 20, aldh5a1−/− mice had elevated C6 dicarboxylic (adipic acid) and C14 carnitines and threonine, combined with a significantly elevated ratio of threonine/[aspartic acid + alanine], in comparison to aldh5a1+/+ mice. Conversely, at DOL 42 aldh5a1−/− mice manifested decreased short chain carnitines (C0-C6), valine and glutamine, in comparison to aldh5a1+/+ mice. Guanidino species, including creatinine, creatine and guanidinoacetic acid, evolved from normal levels (DOL 20) to significantly decreased values at DOL 42 in aldh5a1−/− as compared to aldh5a1+/+ mice. Our results provide a novel temporal snapshot of the evolving metabolic profile of aldh5a1−/− mice while highlighting new pathomechanisms in SSADHD.",
keywords = "Acylcarnitines, aldh5a1 mice, Amino acids, Dried bloodspots, GABA shunt, Guanidino-metabolites, Succinic semialdehyde dehydrogenase (SSADH) deficiency (SSADHD), β-oxidation",
author = "Madalyn Brown and Coleman Turgeon and Piero Rinaldo and Roullet, {Jean Baptiste} and Gibson, {K. Michael}",
year = "2019",
month = "12",
doi = "10.1016/j.ymgme.2019.10.003",
language = "English (US)",
volume = "128",
pages = "397--408",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Temporal metabolomics in dried bloodspots suggests multipathway disruptions in aldh5a1−/− mice, a model of succinic semialdehyde dehydrogenase deficiency

AU - Brown, Madalyn

AU - Turgeon, Coleman

AU - Rinaldo, Piero

AU - Roullet, Jean Baptiste

AU - Gibson, K. Michael

PY - 2019/12

Y1 - 2019/12

N2 - Succinic semialdehyde dehydrogenase (SSADH) deficiency (SSADHD; OMIM 271980) is a rare disorder featuring accumulation of neuroactive 4-aminobutyric acid (GABA; γ-aminobutyric acid, derived from glutamic acid) and 4-hydroxybutyric acid (γ-hydroxybutyric acid; GHB, a short-chain fatty acid analogue of GABA). Elevated GABA is predicted to disrupt the GABA shunt linking GABA transamination to the Krebs cycle and maintaining the balance of excitatory:inhibitory neurotransmitters. Similarly, GHB (or a metabolite) is predicted to impact β-oxidation flux. We explored these possibilities employing temporal metabolomics of dried bloodspots (DBS), quantifying amino acids, acylcarnitines, and guanidino- metabolites, derived from aldh5a1+/+, aldh5a1+/− and aldh5a1−/− mice (aldehyde dehydrogenase 5a1 = SSADH) at day of life (DOL) 20 and 42 days. At DOL 20, aldh5a1−/− mice had elevated C6 dicarboxylic (adipic acid) and C14 carnitines and threonine, combined with a significantly elevated ratio of threonine/[aspartic acid + alanine], in comparison to aldh5a1+/+ mice. Conversely, at DOL 42 aldh5a1−/− mice manifested decreased short chain carnitines (C0-C6), valine and glutamine, in comparison to aldh5a1+/+ mice. Guanidino species, including creatinine, creatine and guanidinoacetic acid, evolved from normal levels (DOL 20) to significantly decreased values at DOL 42 in aldh5a1−/− as compared to aldh5a1+/+ mice. Our results provide a novel temporal snapshot of the evolving metabolic profile of aldh5a1−/− mice while highlighting new pathomechanisms in SSADHD.

AB - Succinic semialdehyde dehydrogenase (SSADH) deficiency (SSADHD; OMIM 271980) is a rare disorder featuring accumulation of neuroactive 4-aminobutyric acid (GABA; γ-aminobutyric acid, derived from glutamic acid) and 4-hydroxybutyric acid (γ-hydroxybutyric acid; GHB, a short-chain fatty acid analogue of GABA). Elevated GABA is predicted to disrupt the GABA shunt linking GABA transamination to the Krebs cycle and maintaining the balance of excitatory:inhibitory neurotransmitters. Similarly, GHB (or a metabolite) is predicted to impact β-oxidation flux. We explored these possibilities employing temporal metabolomics of dried bloodspots (DBS), quantifying amino acids, acylcarnitines, and guanidino- metabolites, derived from aldh5a1+/+, aldh5a1+/− and aldh5a1−/− mice (aldehyde dehydrogenase 5a1 = SSADH) at day of life (DOL) 20 and 42 days. At DOL 20, aldh5a1−/− mice had elevated C6 dicarboxylic (adipic acid) and C14 carnitines and threonine, combined with a significantly elevated ratio of threonine/[aspartic acid + alanine], in comparison to aldh5a1+/+ mice. Conversely, at DOL 42 aldh5a1−/− mice manifested decreased short chain carnitines (C0-C6), valine and glutamine, in comparison to aldh5a1+/+ mice. Guanidino species, including creatinine, creatine and guanidinoacetic acid, evolved from normal levels (DOL 20) to significantly decreased values at DOL 42 in aldh5a1−/− as compared to aldh5a1+/+ mice. Our results provide a novel temporal snapshot of the evolving metabolic profile of aldh5a1−/− mice while highlighting new pathomechanisms in SSADHD.

KW - Acylcarnitines

KW - aldh5a1 mice

KW - Amino acids

KW - Dried bloodspots

KW - GABA shunt

KW - Guanidino-metabolites

KW - Succinic semialdehyde dehydrogenase (SSADH) deficiency (SSADHD)

KW - β-oxidation

UR - http://www.scopus.com/inward/record.url?scp=85074691897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074691897&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2019.10.003

DO - 10.1016/j.ymgme.2019.10.003

M3 - Review article

C2 - 31699650

AN - SCOPUS:85074691897

VL - 128

SP - 397

EP - 408

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 4

ER -